# AS01B adjuvant mechanisms and CD4 T cell responses

## Abstract
AS01B adjuvant induces CD4 T cell responses through a two-phase mechanism involving initial transient inflammatory activation followed by sustained IFN-signaling pathway engagement. Studies demonstrate that AS01B triggers early innate responses including IL-6 and CRP peaking at 24 hours post-vaccination, followed by IFN-γ upregulation and activation of IFN-inducible genes (STAT1, IRF1, MX1, CXCL10) after the second dose. This innate activation directly correlates with enhanced CD4+ T cell outcomes, as multi-parametric modeling shows associations between CRP, IL-6, IFN-signaling pathway activation and subsequent CD4 responses. AS01B consistently induces superior CD4 T cell responses compared to AS02A (3.1-fold higher frequencies), AS03 (5.4-fold higher), AS04 (2.8-fold higher), and aluminum adjuvants, with exceptional durability extending 18-36+ months post-vaccination.

The CD4 response polarization induced by AS01B is context-dependent rather than fixed. Protein/AS01B formulations activate PPAR, FcεRI, and TGF-β pathways, inducing Th2/Tfh2-biased responses that correlate with enhanced antibody production and memory B cell frequencies. In contrast, most other AS01B formulations primarily activate IFN-signaling pathways, driving strong Th1 responses characterized by high IFN-γ production. AS01B’s superiority depends on both liposomal delivery and optimal component dosing, as AS01E containing half the MPL/QS-21 produces comparable innate profiles but 2.2-fold lower CD4 responses. The synergistic combination of MPL and QS-21 in liposomes appears critical for maximal CD4 activation.

## Methods
We analyzed 10 sources from an initial pool of 200, using 8 screening criteria. Each paper was reviewed for 6 key aspects that mattered most to the research question. More on methods

## Paper search
We performed a semantic search across over 138 million academic papers from the Elicit search engine, which includes all of [Semantic Scholar](https://www.semanticscholar.org/) and [OpenAlex](https://openalex.org/).

We ran this query: “AS01B adjuvant mechanisms and CD4 T cell responses”

The search returned 200 total results from Elicit. We retrieved 200 papers most relevant to the query for screening.

## Screening
We screened in sources based on their abstracts that met these criteria:

- **AS01B Adjuvant Focus**: Investigates AS01B adjuvant specifically (containing MPL and QS-21 in liposomes)?
- **CD4 T Cell Response Measurement**: Measures CD4 T cell responses as primary or secondary outcomes?
- **Appropriate Study Type**: Human clinical trial or animal study using established laboratory models?
- **AS01B Data Availability**: Includes AS01B data?
- **CD4 T Cell Data Inclusion**: Includes CD4 T cell data?
- **CD4 T Cell Response Focus**: Includes CD4 T cell response data?
- **AS01B Effect Attribution**: Can AS01B effects be isolated in this study?
- **Full Publication Status**: Is this a full-text publication?

## CD4 Responses
We extracted all CD4 T cell response data for AS01B, including:
- **CD4 T cell proliferation or activation markers**
- **Cytokine production by CD4 cells** 
- **CD4 T cell counts or frequencies**
- **Functional assays**
- **Persistence/durability of CD4 responses**
- **Any CD4 subset analysis**

## Comparative adjuvant effects
AS01B demonstrated superior CD4 T cell induction compared to all tested adjuvants. In a comprehensive comparison, AS01B induced CD4 T cell responses 5.4-fold greater than AS03, 2.8-fold greater than AS04, and 2.2-fold greater than AS01E (p<0.001 for all comparisons).

## Mechanistic links between AS01B activation and CD4 T cell responses
Burny et al. established connections between AS01B’s innate mechanisms and CD4 outcomes through multi-parametric modeling. Increased IFN-γ levels after the second injection correlated with enhanced CD4+ T-cell responses. The authors suggested “trained immunity” as a mechanism linking innate responses to sustained CD4+ T-cell responses.

## Synthesis
The evidence reveals AS01B functions through a two-phase mechanism linking innate activation to durable CD4 responses. The Th1/Th2 skewing appears platform-dependent rather than contradictory, enhancing vaccine immunogenicity through complementary mechanisms for cellular immunity and antibody production.